Dapiprazole Hydrochloride

Dapiprazole Hydrochloride (CAS No.: 72822-13-0) is a synthetic small molecule classified as a selective alpha-1 adrenergic receptor antagonist and is primarily positioned as a pharmacological research tool for investigating adrenergic regulation in ocular and peripheral smooth muscle systems, with reported receptor blocking activity consistent with in vitro potency in the nanomolar to micromolar range depending on assay format, receptor subtype context, and species background; mechanistically, it inhibits alpha-1 receptor mediated signaling that is typically coupled to Gq phospholipase C activation, inositol phosphate turnover, intracellular calcium mobilization, and downstream contractile responses, thereby enabling controlled interrogation of sympathetic neurotransmission in vascular, gastrointestinal, and iris radial smooth muscle models, while also supporting experimental paradigms related to withdrawal associated autonomic phenotypes in preclinical neuropharmacology; in biomedical discovery workflows, this compound is commonly used as a reference antagonist in receptor selectivity profiling, pathway deconvolution studies, and phenotypic assay calibration, including cell based calcium flux or second messenger systems and animal studies focused on adrenergic tone, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, and where interpretation is strengthened by appropriate comparators, receptor expression controls, and multiparametric readouts aligned with early stage target validation and mechanism oriented screening.